| These court-cases have two worthy objectives: Correcting this behavior in pharmaceutical co.s in the future and compensating the states & people harmed in the past. Incentivizing restraint and honest advertising is only possible by punishing executives, personally [1]. Especially those in sales. And fair compensation is many, many times this number. So I fail to see how this is anything other than an injustice, and fear that it will take the pressure off of other court cases against opioid sellers. Reading the book "Dreamland" [2] on the opioid crisis changed my life. Even as someone from a part of Ohio hurt by opioids, it's hard to imagine the venality of these people, the callousness of the Mexican drug dealers who swoop in behind them, and the magnitude of suffering their perfect storm concocts. [1] https://news.ycombinator.com/item?id=19669453
[2] https://www.amazon.com/Dreamland-True-Americas-Opiate-Epidem... |
Instead we should be spending more money at the FDA level. The surgeon general should have the resources that say that condition X, the approved drugs are A, B, C, D and E. You can also do in a phased fashion. You always prescribe A. Only if that fails do you prescribe B, etc. There are lots of treatment plans like this already (usually driven by insurance costs) but these could be built by leading physicians in each specialty. There are providers that have the knowledge of what works and doesn't but we do an awful job of capturing it. Most doctors just know what they learned in school 30 years ago or what they can google. We need better codification of successful treatment options for each condition X.